首页> Journal of clinical oncology : official journal of the American Society of Clinical Oncology> Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Abby B,Siegel

第一单位： Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032-3784, USA. aas54@columbia.edu

作者： Abby B,Siegel ^[1] ; Emil I,Cohen ; Allyson,Ocean ; Deborah,Lehrer ; Alec,Goldenberg ; Jennifer J,Knox ; Helen,Chen ; Sean,Clark-Garvey ; Alan,Weinberg ; John,Mandeli ; Paul,Christos ; Madhu,Mazumdar ; Elizabeta,Popa ; Robert S,Brown ; Shahin,Rafii ; Jonathan D,Schwartz

作者单位： Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032-3784, USA. aas54@columbia.edu ^[1]

医学主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);血管生成抑制剂(Angiogenesis Inhibitors);动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);癌, 肝细胞(Carcinoma, Hepatocellular);趋化因子CXCL12(Chemokine CXCL12);无病生存(Disease-Free Survival);人类(Humans);输注, 静脉内(Infusions, Intravenous);肝肿瘤(Liver Neoplasms);磁共振血管造影术(Magnetic Resonance Angiography);男(雄)性(Male);中年人(Middle Aged);新生血管化, 病理性(Neovascularization, Pathologic);血管内皮生长因子A(Vascular Endothelial Growth Factor A)

DOI 10.1200/JCO.2007.15.9947

PMID 18565886

发布时间 2024-06-10

基金项目

UL1 RR024156/RR/NCRR NIH HHS/United States K23 CA090584/CA/NCI NIH HHS/United States K23 CA-90584/CA/NCI NIH HHS/United States K24 CA100287/CA/NCI NIH HHS/United States K24 CA-100287-05/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交